- Abstract:
-
Cholinergic replacement therapy for Alzheimer's disease using existing cholinesterase inhibitors is compromised by short duration, meagre benefits restricted to subgroups of patients, and peripheral toxicity. Heptyl physostigmine is a lipophilic carbamate derivative of physostigmine. In rhesus monkeys, heptyl physostigmine (0.2-0.9 mg/kg i.m.) fully reversed a scopolamine-induced cognitive impairment. Following oral administration in squirrel monkeys, heptyl physostigmine (8 mg/kg) induced lo...
Expand abstract - Publication status:
- Published
- Journal:
- Journal of the neurological sciences
- Volume:
- 107
- Issue:
- 2
- Pages:
- 246-249
- Publication date:
- 1992-02-05
- DOI:
- EISSN:
-
1878-5883
- ISSN:
-
0022-510X
- URN:
-
uuid:1733eaa0-4373-4d39-a814-cd5de6b76774
- Source identifiers:
-
10495
- Local pid:
- pubs:10495
- Copyright date:
- 1992
Journal article
Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record